He Left MIT At 22 To Solve A Problem Investors Didn’t Get. Now His Company Is Worth $6 Billion
Ten years ago, Sajith Wickramasekara dropped out of the Computer Science program at MIT to build something new: a software company that helps life science researchers better organize their lab work. Today, Benchling is the “Google Docs for R&D” and serves over 200,000 researchers across 700 companies. But back in 2012, that value proposition was less clear. When Benchling first got started, software investors weren’t scrambling to fund digital notebooks in the cloud and, even more so, weren’t familiar with biotech’s problem spaces. That made the initial days especially difficult, but ultimately pushed Wickramasekara and co-founder Ashu Singhal to stay heads-down on engineering and product development. The hard work wasn’t unwarranted; Wickramasekara knew there was something there. In high school and college, he spent his time outside of class working in research labs. And over time, he had become increasingly wary of how much the R&D industry relies on pens and paper. PROMOTED While mo
Innovation Enterprise Tech He Left MIT At 22 To Solve A Problem Investors Didn’t Get. Now His Company Is Worth $6 Billion By Steven Li , Former Contributor. Forbes contributors publish independent expert analyses and insights. Sharing the stories of successful founders Mar 21, 2022, 09:00am EDT Mar 23, 2022, 04:12am EDT This article is more than 4 years old. Benchling co-founders Sajith Wickramasekara (CEO) and Ashu Singhal (President) Benchling Ten years ago, Sajith Wickramasekara dropped out of the Computer Science program at MIT to build something new: a software company that helps life sci
Explore this link on the map →related reading
- Tech vs Biotech - Celine Haliouacelinehh.com
- How the most successful B2B startups came up with their original idealennysnewsletter.com
- There aren't enough smart people in biology doing something boringowlposting.com
- How Software in the Life Sciences Actually Works (And Doesn’t Work) - New Sciencenewscience.org
- How Life Sciences Actually Work: Findings of a Year-Long Investigation - Alexey Guzeyguzey.com
- “Build What’s Fundable” - by Kyle Harrison - Investing 101investing101.substack.com
- Biotech Startups: Move Slow and Fix Things - Stanford Biotechnology Groupstanfordbiotechgroup.com
- Excuse me, is there a problem?longform.asmartbear.com
- Vanta's Path to Product-Market Fit — Solve the Customer’s Problem, Then Write Codereview.firstround.com
- Why there are no cracked biotechnologists?partialagonism.substack.com
- Hub-and-Spoke Biotechs: BridgeBio - by Elliot Hershbergcenturyofbio.com
- Biotech’s Dulcius Ex Asperis: The Way Through This Downturn - RApportrapport.bio